Population-based data have documented a continued increase in NTM prevalence since
2000. Annual prevalence in North American and Australia ranges from 3.2–9.8 per 100,000 …

The 2020 clinical practice guideline for the treatment of non-tuberculous mycobacterial
pulmonary disease (NTM-PD) by the American Thoracic Society, European Respiratory …

Non-tuberculous mycobacteria (NTM) are emerging worldwide as significant causes of
chronic pulmonary infection, posing a number of challenges for both clinicians and …

Numerous studies have revealed a continuous increase in the worldwide incidence and
prevalence of non-tuberculous mycobacteria (NTM) diseases, especially pulmonary …

Background The advent of macrolides has led to therapeutic advances in the treatment of
Mycobacterium avium complex lung disease (MAC-LD). The aim of this study was to …

Survival implications of nontuberculous mycobacterial pulmonary disease (NTM-PD) and
NTM pulmonary isolation without disease (NTM-PI) are unclear. To study deaths associated …

SETTING: Tertiary referral center, National Institutes of Health (NIH), USA. OBJECTIVE: To
estimate the mortality rate and its correlates among persons with pulmonary non …

Pulmonary non-tuberculous mycobacterial (NTM) infections particularly caused by
Mycobacterium avium complex (MAC) and Mycobacterium abscessus (MAB) are becoming …

Objective The prevalence of Marfan syndrome (MFS) is estimated to be 1 in 10,000 to
15,000 individuals, but the phenotype of MFS may not be apparent and hence its diagnosis …

The nontuberculous mycobacteria (NTM), defined as any mycobacterial pathogen other than
Mycobacterium tuberculosis or Mycobacterium leprae, are a diverse group of pathogens that …